Merck returns antifungal rights to Scynexis
Research Triangle Park, N.C. — Merck (NYSE: MRK)is returning all of the rights of an antifungal compound to Scynexis after the drug giant decided it did not want to pursue that compound anymore....
Please Log In to add a comment.
Best of TechWire Insider
- Microsoft paints sunny earnings picture
- Crowdfunding bill moves - again - as part of different legislation
- AT&T already seeking permits for rollout of ultrafast network
- Latest stats show institutional venture capital in N.C. becoming a joke
- With cities on board, N.C. Next Generation Network is rolling toward first big deployment target
- Is IBM-Apple deal a slap in the face for Lenovo?
- A rare look into economic recruitment, requirements: Cary's disappearing 1,237 jobs document
- N.C. Senate committee to consider crowdfunding bill
- NCTA renames its '21 Awards,' to honor winners with 'Beacon'
- Vivek Wadhwa's book 'Innovating Women' hits markets Sept. 2